Recent research involving over 5,000 individuals with cardiovascular disease has shown a significant correlation between hope and improved health outcomes. High levels of hopefulness were associated with reduced angina, decreased post-stroke fatigue, a higher quality of life, and a lower risk of death. These findings were presented at the British Cardiovascular Society meeting in Manchester. The studies utilized questionnaires to measure hope, defining it as a positive motivational state based on agency and goal-setting. This research adds to the growing body of evidence on the mind-body connection, particularly the impact of optimism and pessimism on physical health. While the exact mechanisms behind these effects remain unclear, the potential for harnessing positive thinking in clinical settings is being explored.
Pitt Cardiothoracic Surgery Department
@UPMC_CTSurgery
·
21h Top abstract three years in a row! Dr. Yeahwa Hong presents “Utilization of Hearts Donated After Circulatory Death Improves All-Cause Survival in Candidates with Durable Left Ventricular Assist Devices” at #ASAIO2025
Ahmed Bennis
@drbennisahmed
·
Jun 3 Heart Failure CONFIRMATION-HF
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine efficacy and safety of treatment in patients hospitalized with HF
Heart Failure CONFIRMATION-HF | Sutter Health https://sutteremployer.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414…
The Heart
@ZHeart11768530
·
Jun 1 Evidence-Based Care for Worsening Heart FailureState-of-the-Art #2024Review #OpenAccess
#Hospitalization is an opportunity to optimize care and change disease trajectory in #heartfailure
https://sciencedirect.com/science/article/pii/S2772963X24003260?via%3Dihub…
#FOAMed #MedEd #medstudent #paramedic #Cardiology
Andrew J Sauer MD
@AndrewJSauer
·
Jun 5 #CONFIDENCE results: now explore HF
#CONFIRMATION-HF, we enrolled 12th patient
@MidAmericaHeart
today!
Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF) | http://ClinicalTrials.gov
Brendon Neuen
@brendonneuen
·
Jun 5 Fantastic to see CONFIDENCE trial results presented at #ERA25 and in
@NEJM
Prevention of CV events, esp. heart failure, is probably most compelling rationale for rapid initiation of combo therapy in CKD/T2D, with benefits on kidney failure accruing gradually over time
AURORA
@aeriyze
·
6h What’s more, a study conducted by the European Heart Journal found that people who felt happy had a 22% lower risk of developing heart disease!——
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
